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The worldwide incidence of malignant mesothelioma isincreasing. This is a highly aggressive asbestos-related
tumor with a median survival of less than a year.1 Treat-
ment options have been limited and have done little to
extend the median survival, although some strategies, such
as complete tumor resection in patients with early disease,
seem promising.2,3
Serum markers have been useful for the clinical man-
agement of different cancers.4 Currently no serum markers
are in routine use for the clinical management of patients with
mesothelioma. We have therefore evaluated a newly de-
scribed tumor marker, soluble mesothelin related protein
(SMRP),5 in patients with mesothelioma.
SMRP is a member of the mesothelin family of pro-
teins. Little is known of the function of this family of
proteins. Mesothelin itself is a 40kDa cell surface protein that
is present on normal mesothelial cells and on some cancers
including mesothelioma, ovarian, and pancreatic cancer.6 It is
believed that alternative splicing of the mesothelin gene
results in the production of SMRP, a putatively soluble
protein with an N-terminal region identical to that of me-
sothelin but with a different C-terminal. Using a double-
determinant enzyme-linked immunosorbent assay, SMRP has
been detected in the serum of patients with ovarian cancer
and in a few patients with other cancers5
PATIENTS AND METHODS
Patients and Controls
Serum samples were obtained from patients presenting
at the respiratory clinics of either the Sir Charles Gardiner
Hospital or the Hollywood Specialist Centre in Perth, West-
ern Australia. Forty-four patients (39 male, 5 female) with
cytologically or histopathologically confirmed mesothelioma
were included in this study. Of these patients, 25 had epithe-
lial tumors, four had sarcomatoid, and 15 were unclassified.
Serum samples from healthy individuals were included as
controls. Samples from patients with other malignancies and
with non-malignant lung and pleural effusions were exam-
ined to be certain that SMRP levels were not increased in
other diseases. To determine whether asbestos exposure per
se influenced SMRP levels, serum from individuals with a
history of asbestos exposure and follow-up information for
approximately 8 years, were also studied. These individuals
form part of an on-going surveillance program of people who
worked or lived in Wittenoom, Western Australia.7,8
SMRP Assays
SMRP concentrations were determined by enzyme-
linked immunosorbent assay using monoclonal antibodies
(OV569 and 4H3) that bind to different SMRP epitopes.5
Recently, Fujirebio Diagnostics Incorporated acquired the rights
for the use of the SMRP assay and kindly provided us with kits.
Quantitative measurements were made against reference stan-
dards prepared by the manufacturer. SMRP levels were
determined following the manufacturer’s instructions.
RESULTS
SMRP concentrations in the serum of patients with
established mesothelioma ranged from 0.35 to 78 nM. For the
population of 44 individuals, the mean  standard deviation
concentration was 15.33  20.48 nM. SMRP levels in pa-
tients with mesothelioma were significantly higher than those
in healthy controls with or without a history of asbestos
exposure (0.925  0.831 and 1.455  1.524 respectively;
P  0.001).
Increased levels of serum SMRP were only observed in
three of the 169 patients with malignant or benign pulmonary
or pleural diseases (Table 1). One of these three SMRP-
positive patients had non-small cell lung cancer, another had
cryptogenic fibrosing alveolitis-idiopathic pulmonary fibro-
sis, and the third had asbestosis. None of the patients with
lung adenocarcinoma (n  7) or with pleural effusion (n 
20), conditions that frequently exhibit symptoms overlapping
with mesothelioma, were SMRP-positive.
To determine the clinical value of SMRP concentra-
tions as an aid to mesotheloma diagnosis, we measured levels
in 20 people who presented at the clinic and had a serum
sample available within the 2-month period of pathologically
confirmed mesothelioma diagnosis. SMRP concentrations in
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these symptomatic individuals were significantly different
from the above healthy control populations, with or without
asbestos exposure (P  0.001). SMRP concentrations at the
time of mesothelioma diagnosis ranged from 0.982 to 35.45
nM, with a mean value of 6.9  9.9 nM. Of note, four of the
20 patients with early-stage mesothelioma had tumors with a
predominantly sarcomatoid histology; the serum SMRP lev-
els in the sarcomatoid patients were lower than those in the
patients with predominantly epithelial tumors (data not
shown).
As previously noted, in this study, we measured SMRP
concentrations in 40 healthy controls with a history of asbes-
tos exposure. These individuals were part of a public health
epidemiology survey that annually monitors people who
worked or lived in Wittenoom, Western Australia, the site of
a large asbestos mining operation.7,8 At the time the 40 serum
samples were collected, all the individuals were healthy.
Interestingly, follow-up data revealed that three people in this
group developed mesothelioma 15, 26, and 69 months later,
and one person developed lung carcinoma 4 years later. The
level of SMRP was higher in these dour individuals than in
the people who had not, at the close of the study, died from
malignancy (Table 2).
A possible confounding element to this study is the
stability of SMRP in serum stored frozen for several years
and the effect of thawing and refreezing samples. To first
assess the stability of the SMRP protein under different
storage conditions, we measured levels in serum samples that
had been stored for approximately 36 months at either 4ºC,
–20ºC, or –80ºC for three individuals with low, medium, or
high SMRP levels. There was no statistical difference in the
SMRP levels depending on the temperature at which serum
was stored during an approximate 3-year period (data not
shown). We also mimicked a series of freeze-thaw cycles
using serum from three individuals with low, medium, or
high SMRP levels. Figure 1 shows the relative mean level of
the SMRP in samples after one, two, five, and 10 freeze/thaw
cycles relative to the value determined for the original sam-
ple. There was no statistical difference in the SMRP levels
after 10 freeze/thaw cycles.
DISCUSSION
Most patients with mesothelioma have increased serum
levels of SMRP, which suggests that SMRP is a sensitive marker
for this disease. SMRP also seems to be a specific marker, as
only three of 160 patients with other non-mesothelioma malig-
nant or benign lung or pleural disease had increased serum
SMRP. As SMRP levels were increased in half the patients at
the time they were presenting to the clinic with symptoms and
levels were also elevated in pleural effusions (data not shown),
measurement of this biomarker could be a useful adjunct to the
clinician’s repertoire for mesothelioma diagnosis.
Much interest surrounds the use of serum tumor mark-
ers for screening healthy populations for malignancy with the
aim of identifying early-stage disease and providing early
treatment.9 In general, asbestos-exposed individuals are com-
pliant to screening strategies. In this small study, we showed
that SMRP levels were significantly increased in three people
who were apparently healthy but were diagnosed 1 to 5 years
later with mesothelioma and in one individual who died of
lung adenocarcinoma 4 years after the positive SMRP serum
sample. We are currently extending these studies to include a
greater number of asbestos-exposed subjects, but the prelim-
inary results coupled with the apparent stability of the protein
we report herein suggests that the test may be valuable in
screening programs for which samples may need to be col-
lected under field conditions. However, as only half the
mesothelioma patients have increased SMRP levels at the
TABLE 1. SMRP and Disease
Condition
SMRP-positive
samples (n)
SMRP-positive
samples (%)
Mesothelioma 37/40 84
Other malignancies 1/36 2.8
Non-malignant lung and pleural
disease; asbestos-related
2/124 1/40 1.6
Healthy controls, non-asbestos
exposed
0/28 0
Healthy controls
Asbestos-exposed (total) 7/40 17
Malignancy-free 3/36
Pre-malignancy 4/4
SMRP, soluble mesothelin related protein.
TABLE 2. SMRP and Patient Condition
Condition n Mean  SD
Healthy 36 1.016  0.61
Mesothelioma 3 3.52  1.38
Lung cancer 1 8.49
SMRP, soluble mesothelin related protein. FIGURE 1.
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time of diagnosis, we are currently investigating whether
measuring a combination of biomarkers, possibly including
the recently described osteopontin,10 would provide the
power necessary for an effective screening program.
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